Vetrovec G W, Parker V E, Cole S, Procacci P M, Tabatznik B, Terry R
Department of Medicine, Medical College of Virginia, Richmond.
Am J Med. 1987 Dec 21;83(6B):24-9. doi: 10.1016/0002-9343(87)90633-4.
To compare the clinical efficacy and dose equivalency of standard nifedipine versus a new gastrointestinal therapeutic system (GITS) formulation of nifedipine, 98 patients with chronic stable angina pectoris participated in a 14-week, multicenter, open-label, crossover trial. All patients were administered nifedipine capsules for one month prior to study entry and continued receiving other antianginal, non-calcium blocker medications. Ninety-one patients (93 percent), 80 men and 11 women, mean age 62 +/- 1 years, completed the trial, which included two weeks receiving standard nifedipine followed by 12 weeks receiving nifedipine GITS starting at a dosage equal to the 24-hour total dose of nifedipine capsules and titrated upward as necessary. However, throughout the trial, mean nifedipine dosage was similar on nifedipine GITS compared with standard nifedipine. Angina frequency was significantly less with nifedipine GITS at Weeks 6, 10, and 14 (0.8 episodes/week) compared with baseline with standard nifedipine (1.3 episodes/week, p less than 0.05). Likewise, nitroglycerin consumption was also less at Weeks 6, 10, and 14, but only significantly less at Week 6 (nifedipine 1.2/week versus nifedipine GITS at six weeks, 0.7/week; p less than 0.05). Resting hemodynamic parameters, including systolic and diastolic blood pressure and heart rate, were not significantly different with standard nifedipine versus nifedipine GITS during the 12-week study. Total incidences of side effects were similar for both treatments (standard nifedipine, 16; nifedipine GITS, 17). However, incidence of vasodilator side effects (flushing, dizziness, and light-headedness) was significantly less frequent with nifedipine GITS (standard nifedipine, 12; nifedipine GITS, six; p less than 0.05). Thus, results from this open-label, crossover trial suggest that nifedipine GITS dosing is similar to multidose standard nifedipine with equivalent 24-hour efficacy for nifedipine GITS.
为比较标准硝苯地平与新型胃肠道治疗系统(GITS)剂型硝苯地平的临床疗效和剂量等效性,98例慢性稳定型心绞痛患者参与了一项为期14周的多中心、开放标签、交叉试验。所有患者在研究入组前服用硝苯地平胶囊1个月,并继续接受其他抗心绞痛、非钙通道阻滞剂药物治疗。91例患者(93%),80名男性和11名女性,平均年龄62±1岁,完成了试验,试验包括2周接受标准硝苯地平治疗,随后12周接受硝苯地平GITS治疗,起始剂量等于硝苯地平胶囊的24小时总剂量,并根据需要向上滴定。然而,在整个试验过程中,硝苯地平GITS的平均硝苯地平剂量与标准硝苯地平相似。与标准硝苯地平基线水平(1.3次/周,p<0.05)相比,硝苯地平GITS在第6、10和14周时心绞痛发作频率显著降低(0.8次/周)。同样,硝酸甘油消耗量在第6、10和14周时也较少,但仅在第6周时显著减少(硝苯地平1.2次/周,而第6周时硝苯地平GITS为0.7次/周;p<0.05)。在为期12周的研究中,包括收缩压、舒张压和心率在内的静息血流动力学参数在标准硝苯地平与硝苯地平GITS之间无显著差异。两种治疗的副作用总发生率相似(标准硝苯地平组16例,硝苯地平GITS组17例)。然而,硝苯地平GITS引起的血管扩张副作用(潮红、头晕和眩晕)发生率显著较低(标准硝苯地平组12例,硝苯地平GITS组6例;p<0.05)。因此,这项开放标签、交叉试验的结果表明,硝苯地平GITS的给药方式与多剂量标准硝苯地平相似,硝苯地平GITS具有等效的24小时疗效。